Formulary Search Results for: CALCIUM AND VITAMIN D
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use only in patients in whom other non-biologic systemic treatments (methotrexate, ciclosporin and acitretin) are not appropriate, or have failed and who are considered unsuitable for biologic therapy given they current disease state or personal preference,
13.3 Local anaesthetics and antipruritics - View Category
Restrictions:
Treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. Restricted to in-centre haemodialysis use only, in patients with an inadequate response to best supportive care for reducing itch.
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Atopic dermatitis:
The use in the treatment of moderate-to-severe atopic dermatitis in adults is restricted to use in accordance with local guidelines in patients who have had an inadequate response to existing systemic immunosuppressants such as ciclosporin, or in whom such treatment is considered unsuitable.
Prurigo nodularis:
Treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.
7.3.2.1 Oral progestogen-only contraceptives - View Category
1.2 Antispasmodics and other drugs altering gut motility - View Category
Prescribing Notes:
In April 2014, following a Europe-wide review, the MHRA issued advice to healthcare professionals relating to the use of domperidone, restricting its use to relief or nausea and vomiting, advising that it should be used at the lowest effective dose for the shortest possible time, and highlighting changes to the contraindications, dosing and duration of treatment of the medicine.
Domperidone is no longer licensed in patients weighing less than 35 kg because of a lack of evidence for benefit.
The full advice from the MHRA and details of the 2019 post-publication note can be accessed here.
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use in accordance with local guidelines for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy who have failed at least one current systemic immunosuppressant due to intolerance, contraindication or inadequate disease control.
Prescribing Notes:
Following a MHRA review in April 2023, the risk of increased incidence of malignancy, major adverse cardiovascular events (MACE), serious infections, venous thromboembolism (VTE) and mortality, when compared to those treated with tumour necrosis factor (TNF)-alpha inhibitors, were are considered a class effects across JAK inhibitors used for chronic inflammatory disorders and therefore it is advised to avoid prescribing these medicines unless there are no suitable alternatives in patients with the following risk factors:
- age 65 years or older
- current or past long-time smoking
- other risk factors for cardiovascular disease or malignancy
Please see further details of the review here.
8.3.2 Progestogens - View Category
3.1.2.1 Antimuscarinic combination inhalers - View Category
3.7 Mucolytics - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
Responsibility for initiation, review and any necessary monitoring rests with specialist service.